Fidaxomicin monotherapy versus standard therapy combined with bezlotoxumab for treating patients with Clostridioides difficile infection at high risk of recurrence: a matched cohort study.
Escudero-Sanchez R, Muriel García A, García Fernández S, Valencia Alijo A, Tasias Pitarch M, Merino De Lucas E, Gutierrez Rojas A, Ramos Martínez A, Salavert Lletí M, Giner L, Ruíz Ruigomez M, García Basas L, Fernández Fradejas J, Olmedo Sampedrio M, Cano Yuste A, Díaz Pollán B, Rodríguez Hernández MJ, Martín Segarra O, Sáez Bejar C, Armiñanzas Castillo C, Gutiérrez B, Rodríguez-Pardo D, De La Torre Cisneros J, López Medrano F, Cobo Reinoso J.
Escudero-Sanchez R, et al. Among authors: fernandez fradejas j.
J Antimicrob Chemother. 2022 Jun 29;77(7):1996-2002. doi: 10.1093/jac/dkac106.
J Antimicrob Chemother. 2022.
PMID: 35403189